Prostate Health - Global Strategic Business Report

The global market for Prostate Health was valued at US$33.8 Billion in 2024 and is projected to reach US$51.2 Billion by 2030, growing at a CAGR of 7.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Prostate Health market.

Global 'Prostate Health' Market - Why Is Proactive Care Becoming a Global Men’s Health Imperative?

Is the Aging Population Raising the Urgency Around Prostate Health?

Prostate health is becoming a central concern in global healthcare systems, largely due to the rapid aging of the male population and increased awareness around urological conditions. Prostate-related disorders such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer are increasingly prevalent among men aged 50 and above, creating steady demand for preventive, diagnostic, and therapeutic solutions. Public health campaigns and enhanced screening protocols have led to early detection, contributing to better prognosis and a wider treatment window. Additionally, lifestyle-related risk factors - such as obesity, smoking, and sedentary habits - are exacerbating the incidence of prostate issues, even in younger age groups. The expansion of diagnostic tools like PSA testing, MRI, and transrectal ultrasound is making prostate health monitoring more accessible and precise. Governments and health organizations are integrating prostate care into regular male health checkups, particularly in North America, Europe, and parts of Asia, further boosting awareness and demand for clinical interventions.

Are Innovations in Diagnosis and Treatment Enhancing Clinical Outcomes?

The prostate health market is benefiting significantly from advancements in diagnostic and therapeutic technologies. Minimally invasive surgical techniques, such as laser therapy, TURP (transurethral resection of the prostate), and newer robotic-assisted procedures, are reducing recovery time and improving quality of life for patients. Pharmacological innovation is also playing a key role; newer generations of alpha-blockers, 5-alpha reductase inhibitors, and hormone therapies are offering more targeted symptom management with fewer side effects. Diagnostic imaging is becoming more precise with multiparametric MRI and biomarker-based tests allowing earlier and more accurate differentiation between benign conditions and malignancies. Furthermore, research into immunotherapy and radiopharmaceuticals is showing promise in treating advanced-stage prostate cancer. Digital health tools, such as tele-urology platforms and mobile health apps, are supporting patient compliance, symptom tracking, and virtual consultations. As diagnostics and therapeutics become more integrated, holistic care pathways are emerging, improving clinical workflows and patient outcomes.

Is Male Health Awareness and Consumer Behavior Driving Demand?

Societal shifts in how men approach their health are transforming the prostate health landscape. Traditionally underdiagnosed due to stigma and neglect, prostate conditions are now receiving increased attention thanks to advocacy from celebrities, medical societies, and digital influencers. Younger generations are more proactive about preventive care, participating in regular checkups and genetic screenings. Direct-to-consumer health platforms and home testing kits are giving men more autonomy in managing their health, while pharmacies and primary care clinics offer greater accessibility to prostate-specific services. The growing emphasis on sexual wellness and quality of life is also pushing patients to seek early treatment for conditions like BPH and erectile dysfunction, which are often interlinked with prostate health. Men are becoming more educated on the long-term implications of prostate disease, such as incontinence or cancer, and are therefore more willing to invest in premium diagnostics, second opinions, and ongoing care regimens. These behavioral trends are gradually shifting the market from reactive treatment toward a more preventive, personalized, and patient-centric model.

The Growth in the Prostate Health Market Is Driven by Several Factors…

The growth in the prostate health market is driven by several factors related to demographic trends, evolving diagnostics, and shifting consumer behavior. Technological advancements in minimally invasive procedures, biomarker testing, and imaging modalities are allowing for earlier diagnosis and tailored interventions. From an end-use perspective, the rising patient volumes in urology clinics, specialty hospitals, and outpatient centers - especially in aging economies - are pushing demand for comprehensive screening and treatment services. Consumer preferences are also evolving, with increased acceptance of telehealth, personalized medicine, and at-home testing solutions influencing how care is delivered and consumed. Healthcare infrastructure expansion, particularly in emerging markets, is enabling broader access to prostate health services. Moreover, the pharmaceutical pipeline for prostate-related conditions is robust, with numerous clinical trials focused on novel hormonal therapies and combination regimens. The intersection of medical innovation, patient awareness, and systemic support is creating a fertile environment for the sustained growth of the prostate health market globally.

Report Scope

The report analyzes the Prostate Health market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Disease Type (Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type, Prostate Cancer Disease Type); Treatment (Chemotherapy Treatment, Hormone Therapy Treatment, Immunotherapy Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Prostatitis Disease segment, which is expected to reach US$27.4 Billion by 2030 with a CAGR of a 5.7%. The Benign Prostatic Hyperplasia Type segment is also set to grow at 9.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $9.2 Billion in 2024, and China, forecasted to grow at an impressive 11.0% CAGR to reach $10.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Prostate Health Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Prostate Health Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Prostate Health Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 37 companies featured in this Prostate Health market report include:

• Abbott Laboratories
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Clovis Oncology, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• Ferring Pharmaceuticals Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• ProArc Medical Ltd.
• Quibim
• Sanofi
• Siemens Healthineers AG
• Veru Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry